Identification
- Summary
Magaldrate is an antacid used to treat various conditions in the GI tract, such as esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux.
- Generic Name
- Magaldrate
- DrugBank Accession Number
- DB08938
- Background
Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Magaldrate (DB08938)
- Weight
- Average: 1115.3
Monoisotopic: 1111.7570627 - Chemical Formula
- Al5H33Mg10O40S2
- Synonyms
- Aluminium magnesium hydroxide sulfate hydrate
- Aluminum magnesium hydroxide sulfate hydrate
- Aluminum magnesium hydroxide sulphate hydrate
- Hydrate magnesium aluminate activated sulfate
- Magaldrate
- Magaldrato
- Magaldratum
- Magnesium aluminate hydrate
- Monalium hydrate
- External IDs
- AY 5710
- AY-5710
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acid indigestion ••• ••• Treatment of Bloating ••• ••• Treatment of Heartburn ••• ••• Treatment of Sour stomach ••• ••• Prophylaxis of Stress ulcer ••• ••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Aluminium oxide: absorbed Al ions are eliminated in the urine (0.1-0.5 mg of Al in aluminium-containing antacid is absorbed from standard daily doses of antacid) while insoluble or poorly absorbed Al salts in the intestines are excreted through the feces.
Magnesium oxide: absorbed Mg ions (up to 30%) are eliminated in the urine, unabsorbed is excreted in the feces.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetaminophen Magaldrate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. Acetophenazine Magaldrate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Magaldrate. Alfacalcidol The serum concentration of Magaldrate can be increased when it is combined with Alfacalcidol. Alimemazine Magaldrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Avoid alcohol.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Almadrat T (Actavis) / Almagel T (Balkanpharma) / Antashin (Standard) / Bemolan (Nycomed) / Cremag (Zuoz) / Glysan (Riemser) / Lowsium (Rugby) / Magacid (Purzer) / Malugastrin (Polfa Lódz) / Riopan (Nycomed) / Sanaflat (Perumed)
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Riopan Chewable Tablets 480mg Tablet 480 mg Oral Wyeth Ayerst Canada Inc. 1994-12-31 2002-07-31 Canada 
Riopan Sus 480mg/5ml Suspension 480 mg / 5 mL Oral Whitehall Robins Inc. 1993-12-31 2002-07-19 Canada Riopan Suspension 480mg/5ml Suspension 480 mg / 5 mL Oral Wyeth Ayerst Canada Inc. 1994-12-31 2002-07-31 Canada Riopan Tab 480mg Tablet 480 mg Oral Whitehall Robins Inc. 1993-12-31 2002-07-19 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ASIDOPAN PLUS 200 ML SUSPANSIYON Magaldrate (540 mg/5ml) + Simethicone (20 mg/5ml) + Sodium cation (1 mg/5ml) Suspension Oral TURGUT İLAÇLARI A.Ş. 2006-10-02 Not applicable Turkey 
ASIDOPAN PLUS 30 CIGNEME TABLET Magaldrate (480 mg) + Simethicone (20 mg) Tablet, chewable Oral TURGUT İLAÇLARI A.Ş. 2006-10-04 Not applicable Turkey ASIDOPAN PLUS 60 CIGNEME TABLET Magaldrate (480 mg) + Simethicone (20 mg) + Sodium cation (1 mg) Tablet, chewable Oral TURGUT İLAÇLARI A.Ş. 2006-10-04 Not applicable Turkey ASIPODAN PLUS FORTE ÇIĞNEME TABLETI, 20 ADET Magaldrate (1080 mg) + Simethicone (20 mg) Tablet, chewable Oral TURGUT İLAÇLARI A.Ş. 2020-08-14 Not applicable Turkey ASIPODAN PLUS FORTE ÇIĞNEME TABLETI, 30 ADET Magaldrate (1080 mg) + Simethicone (20 mg) Tablet, chewable Oral TURGUT İLAÇLARI A.Ş. 2020-08-14 Not applicable Turkey
Categories
- ATC Codes
- A02AD02 — Magaldrate
- A02AD — Combinations and complexes of aluminium, calcium and magnesium compounds
- A02A — ANTACIDS
- A02 — DRUGS FOR ACID RELATED DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Alimentary Tract and Metabolism
- Alkalies
- Aluminium Compounds
- Aluminum and magnesium containing antacids
- Anions
- Antacids
- Antacids With Antiflatulents
- Drugs for Acid Related Disorders
- Electrolytes
- Gastric Acid Lowering Agents
- Gastrointestinal Agents
- Hydroxides
- Ions
- Magnesium Compounds
- Metal cations
- Metal divalent cations
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 6V88E24N5T
- CAS number
- 74978-16-8
- InChI Key
- SPPNVMTVMQOKSC-UHFFFAOYSA-A
- InChI
- InChI=1S/5Al.10Mg.2H2O4S.32H2O/c;;;;;;;;;;;;;;;2*1-5(2,3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h;;;;;;;;;;;;;;;2*(H2,1,2,3,4);32*1H2/q5*+3;10*+2;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/p-35
- IUPAC Name
- pentaaluminium(3+) decamagnesium(2+) hydrate hentriacontahydroxide disulfate
- SMILES
- O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
References
- Synthesis Reference
U.S. Patent 2,923,660.
- General References
- Kurtz W: [A layered lattice antacid with long-term effectiveness. Profile of action and safety exemplified by magaldrate]. Fortschr Med. 1993 Feb 28;111(6):93-6. [Article]
- Varas Lorenzo MJ, Lopez Martinez A, Gordillo Bernal J, Mundet Surroca J: [Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer]. Rev Esp Enferm Dig. 1991 Aug;80(2):91-4. [Article]
- External Links
- KEGG Drug
- D04832
- PubChem Compound
- 3086011
- PubChem Substance
- 310264905
- 29151
- ChEMBL
- CHEMBL3833350
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Magaldrate
- MSDS
- Download (94.8 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Gel Oral 8.000 g Tablet, chewable Oral Suspension Auricular (otic) 8.000 g Suspension Oral 800 MG/10ML Tablet Oral 800.00 mg Tablet Oral 800 MG Gel Oral 800 MG Suspension Oral Tablet, chewable Oral Gel Oral 80.0000 mg Suspension Oral 80 MG/ML Tablet Oral 400 MG Gel Oral 1600 mg/10ml Gel Oral 80 mg/ml Suspension Oral 800 mg Tablet, chewable Oral 800 mg Gel Oral Gel Oral 1600 mg Suspension Oral Suspension Oral 480 mg / 5 mL Tablet Oral 480 mg Tablet Oral Tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.84 Chemaxon pKa (Strongest Acidic) -3 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 80.26 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 11.53 m3·mol-1 Chemaxon Polarizability 5.81 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 22, 2014 19:08 / Updated at February 21, 2021 18:52